{"disease":{"id":"tuberculosis-multidrug-resistant","name":"tuberculosis multidrug resistant"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03303963","title":"DIAgnostics for Multidrug Resistant Tuberculosis in Africa","phase":"","overall_status":"COMPLETED","enrollment_count":3356,"lead_sponsor_name":"Dissou AFFOLABI","has_results":false},{"nct_id":"NCT03259269","title":"Expand New Drugs for TB [endTB]","phase":"","overall_status":"COMPLETED","enrollment_count":2804,"lead_sponsor_name":"Partners in Health","has_results":false},{"nct_id":"NCT05117788","title":"Bioneer Q-RFIA Clinical Evaluation","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2350,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT04239326","title":"Clinical Evaluation of tNGS for Diagnosis of DR-TB","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT05871489","title":"Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Harvard Medical School (HMS and HSDM)","has_results":false},{"nct_id":"NCT03728725","title":"Xpert MTB/XDR Clinical Evaluation Trial","phase":"","overall_status":"COMPLETED","enrollment_count":710,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT00685360","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":481,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT03338621","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":455,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT05824871","title":"A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Shanghai Jiatan Pharmatech Co., Ltd","has_results":false},{"nct_id":"NCT03896685","title":"Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Médecins Sans Frontières, France","has_results":false},{"nct_id":"NCT06674291","title":"Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":222,"lead_sponsor_name":"Korea Otsuka Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02573350","title":"A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT05306223","title":"A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":212,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT03237182","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":205,"lead_sponsor_name":"Centre for the AIDS Programme of Research in South Africa","has_results":false},{"nct_id":"NCT01071603","title":"Tuberculosis in China","phase":"","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03086486","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":181,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT02454205","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"University of Cape Town","has_results":false},{"nct_id":"NCT01212003","title":"Training Protocol on the Natural History of Tuberculosis","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05007821","title":"Linezolid Dosing Strategies in Drug-Resistant TB","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":138,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02354014","title":"Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT07170800","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"WestVac Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04179500","title":"A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT02711735","title":"Safety of RUTI® Vaccination in MDR-TB Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Archivel Farma S.L.","has_results":false},{"nct_id":"NCT02365623","title":"An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Janssen Pharmaceutical K.K.","has_results":false},{"nct_id":"NCT04783727","title":"PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis","phase":"NA","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Research Center Borstel","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}